NCT03792958View on ClinicalTrials.gov

Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 26, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Advanced Malignant Solid Tumors
Interventions
DRUG

CM082

CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)

Trial Locations (1)

200120

Shanghai East Hospital, Shanghai

Sponsors

Lead Sponsor

AnewPharma
All Listed Sponsors
collaborator

Shanghai East Hospital

OTHER

lead

AnewPharma

INDUSTRY

NCT03792958 - Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors | Biotech Hunter | Biotech Hunter